This trial studies the practicality of PET/MRI scan for rectal cancer treatment response monitoring and post-treatment observation in patients with stage I-IIIb rectal cancer who are receiving chemo-radiation as part of non-operative management practice. Diagnostic procedures such as PET/MRI, may help identify residual disease or detect disease that has come back in rectal cancer patients managed with non-operative management.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04150705.
PRIMARY OBJECTIVE:
I. To determine the feasibility of positron emission tomography (PET)/ magnetic resonance imaging (MRI) for rectal cancer treatment response assessment and post-treatment surveillance for patients receiving chemoradiation as part of an non-operative management (NOM) strategy.
SECONDARY OBJECTIVE:
I. To estimate the added value of PET/MRI relative to MRI only for detecting residual or recurrent rectal cancer following chemoradiation in patients on an NOM protocol.
OUTLINE:
Patients receive fludeoxyglucose F-18 intravenously (IV), then undergo PET/MRI over up to 1 hour.
After completion of study, patients are followed for up to 5 years.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationSiteman Cancer Center at Washington University
Principal InvestigatorTyler J. Fraum
